MA12.11 A Novel 89Zr-Anti-pd1 Immunopet-Ct May Predict Response to PD-1 Inhibitors in a Lung Cancer Murine Model Receiving Immunotherapy

Immune checkpoint inhibitors (ICIs) have revolutionized lung cancer treatment improving survival outcomes of non-small cell lung cancer (NSCLC) patients. Response assessment of patients on ICIs treatment represents a challenge since an increase in tumor size or the appearance of new lesions might not reflect true disease progression (P) but pseudoprogression (PP), which has been reported in a range of 3-6% in NSCLC treated with ICIs. Conventional 18F-FDG-PET scans do not accurately discriminate P from PP.